Previous 10 | Next 10 |
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that company management will present virtually during the H.C. Wainwright Bioconnect Conference as well as t...
Marinus Pharmaceuticals, Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to five new employees. The Compensation Committee of the Board of Directors of M...
Data from an open-label extension of a phase 3 trial of Marinus Pharmaceuticals (MRNS -7.8%) ganaxolone for CDKL5 deficiency disorder ("CDD") showed the treatment led to a reduction in motor seizures at up to 12 months. The median major motor seizure frequency reduction from baseline was 30.1...
Webcast to be held Monday, December 6 at 1:00 p.m. ET (12:00 p.m. CT) Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced new clinical trial and re...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that nine abstracts highlighting clinical trial and research data have been accepted for poster presentatio...
Marinus Pharmaceuticals, Inc. (MRNS) Q3 2021 Earnings Conference Call November 09, 2021, 08:30 AM ET Company Participants Sasha Damouni - VP, IR and Corporate Communications Scott Braunstein - CEO Joe Hulihan - Chief Medical Officer Steve Pfanstiel - CFO Conference Call Participants Joon Lee ...
The following slide deck was published by Marinus Pharmaceuticals, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Marinus Pharmaceuticals, Inc. 2021 Q3 - Results - Earnings Call Presentation
Marinus Pharmaceuticals (NASDAQ:MRNS): GAAP EPS of -$0.53 beats by $0.12. Revenue of $10.11M beats by $4.95M. Press Release For further details see: Marinus Pharmaceuticals EPS beats by $0.12, beats on revenue
European Medicines Agency has accepted the Marketing Authorization Application for ganaxolone in CDKL5 deficiency disorder for review under accelerated assessment European Commission granted orphan drug designation to ganaxolone in tuberous sclerosis complex; Phase 3 TrustTSC prog...
Marinus Pharmaceuticals (NASDAQ:MRNS) is scheduled to announce Q3 earnings results on Tuesday, November 9th, before market open. The consensus EPS Estimate is -$0.65 (-27.5% Y/Y) and the consensus Revenue Estimate is $5.16M (+2935.3% Y/Y). Over the last 3 months, EPS estimates have seen 4 upw...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of ...
Philadelphia, Pennsylvania--(Newsfile Corp. - July 15, 2024) - Attention Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ: MRNS) Investors. A securities fraud class action lawsuit has been filed against Marinus on behalf of purchasers of Marinus securities between March 17, 20...
RAISE trial met its first co-primary endpoint demonstrating rapid cessation of status epilepticus in a highly refractory patient population The trial failed to achieve statistical significance on the second co-primary endpoint of the proportion of patients not progressing to IV anesthesia...